---
document_datetime: 2023-09-21 18:18:24
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/provenge-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: provenge-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.661375
conversion_datetime: 2025-12-18 11:11:23.907109
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## PROVENGE

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10065          | Periodic Safety Update EU Single assessment - AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELLS ACTIVATED WITH PAP-GM-CSF (SIPULEUCEL- T) product | 07/05/2015                          | n/a                                            |                                  | PRAC Recommendation - maintenance |
| IB/0005              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 07/01/2015                          | n/a                                            |                                  |                                   |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet).

The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0006   | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method   | 17/12/2014   | n/a            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------|
| IB/0004   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                            | 09/12/2014   | n/a authorised |
| PSUV/0001 | Periodic Safety Update                                                                                                                                                                          | 11/09/2014   | n/a            |
| IA/0002   | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system                        | 18/06/2014   | n/a longer     |

## 17/12/2014 n/a 09/12/2014 n/a 11/09/2014 n/a 18/06/2014 n/a Medicinal product no longer authorised